Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14551213 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Lo RK, Cheung H, Wong YH (2003) Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. J Biol Chem 278, 52154-65 14551213
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y705-p - STAT3 (human)
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  293 (epithelial), HEL (erythroid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease
Raf1 kinase inhibitor I decrease
SB202190 no change compared to control
SB203580 no change compared to control
U73122 decrease
KN-62 decrease
staurosporine decrease
calphostin C decrease
AG490 decrease
WHI-P131 decrease
AG1478 decrease
PP2 decrease
radicicol decrease
wortmannin no change compared to control
LY294002 no change compared to control
C5a increase
PTX C5a no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  transcription, altered

S727-p - STAT3 (human)
Orthologous residues
STAT3 (human): S727‑p, STAT3 iso2 (human): S726‑p, STAT3 (mouse): S727‑p, STAT3 iso2 (mouse): , STAT3 iso3 (mouse): S726‑p, STAT3 (rat): S727‑p, STAT3 (cow): S727‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  leukemia, erythroid leukemia
 Relevant cell lines - cell types - tissues:  293 (epithelial), HEL (erythroid)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease
Raf1 kinase inhibitor I decrease
SB202190 no change compared to control
SB203580 no change compared to control
U73122 decrease
KN-62 decrease
staurosporine decrease
calphostin C decrease
AG490 decrease
WHI-P131 decrease
AG1478 decrease
PP2 decrease
radicicol decrease
wortmannin no change compared to control
LY294002 no change compared to control
C5a increase
PTX C5a no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.